FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to the use of mitoxantrone hydrochloride liposome in the manufacture of a medicinal agent for the treatment of ovarian cancer, stomach cancer or squamous cell carcinoma of the head and neck, as well as to a method of treating ovarian cancer, stomach cancer or squamous cell carcinoma of the head and neck in a subject. Use of mitoxantrone hydrochloride liposome in the preparation of a medicinal agent for the treatment of ovarian cancer, gastric cancer or squamous cell carcinoma of the head and neck, where ovarian cancer is difficult to treat with platinum preparations or resistant to treatment with platinum preparations recurrent ovarian cancer, gastric cancer is advanced gastric cancer and squamous cell carcinoma of head and neck is recurrent or metastatic squamous cell carcinoma of head and neck, for which the first-line therapy proved to be ineffective. Method of treating ovarian cancer, gastric cancer or squamous cell carcinoma of the head and neck in a subject, comprising administering to the subject a pharmaceutical composition, containing a therapeutically effective amount of mitoxantrone hydrochloride liposome, where ovarian cancer is difficult to treat with platinum preparations or resistant to treatment with platinum preparations recurrent ovarian cancer, gastric cancer is advanced gastric cancer and squamous cell carcinoma of head and neck is recurrent or metastatic squamous cell carcinoma of head and neck, for which the first-line therapy proved to be ineffective.
EFFECT: group of inventions described above makes it possible to treat difficult to treat with platinum preparations or resistant to treatment with platinum preparations recurrent ovarian cancer, advanced gastric cancer and recurrent or metastatic squamous cell carcinoma of head and neck, for which the first-line therapy proved to be ineffective.
43 cl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
USE OF MITOXANTHRON LIPOSOME FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA | 2019 |
|
RU2804477C2 |
PEGYLATED LIPOSOMAL DOXORUBICINUM IN COMBINATION WITH ECTEINESCIDIN 743 | 2005 |
|
RU2359700C2 |
LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR PREPARING IT | 2007 |
|
RU2494729C2 |
TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION | 2016 |
|
RU2761620C2 |
USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
AGENT FOR TREATING TUMOUR AND KIT CONTAINING LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2768178C2 |
AGENT FOR TREATING A TUMOR AND A KIT CONTAINING A LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2738365C2 |
COMBINATION OF PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN TREATMENT OR PREVENTION OF HEAD AND NECK CANCER | 2014 |
|
RU2672555C2 |
PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
Authors
Dates
2024-06-17—Published
2021-12-14—Filed